icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections
February 12-16, 2022
Back grey_arrow_rt.gif
Phase 2b Efficacy Trial of Mosaic HIV-1 Vaccine Regimen in African Women (Imbokodo)
  CROI 2022 Feb 11-16
Glenda Gray, MBBCH, FCPAED (SA)
Protocol Chair
South Africa Medical Research Council
Cape Town, South Africa
HIV-1 incidence was high in this trial. Unfortunately, this vaccine regimen, although safe, did not provide statistically significant protection against HIV-1 infection in young women and, therefore, the trial was discontinued. An ongoing phase 3 trial (Mosaico) is evaluating the efficacy of an HIV-1 vaccine regimen with a modified boost (Ad26/bivalent gp140) in MSM and transgender individuals in the Americas and Europe. Biomedical interventions are urgently required to reduce the impact of HIV-1 in women in Africa.
We enrolled 18-35 year-old women in a randomized, double-blind, placebo-controlled, phase 2b efficacy trial in Malawi, Mozambique, South Africa, Zambia, and Zimbabwe. Women were randomized 1:1 to a heterologous prime and boost vaccine regimen or placebo administered at Months 0 and 3 (Ad26.Mos4.HIV) and Months 6 and 12 (Ad26.Mos4.HIV+clade C gp140). Pre-exposure prophylaxis was available at no charge. Primary vaccine efficacy (VE) was evaluated from Month 7 to 24 (VE[7-24]) in the per-protocol (PP) cohort. Continuation of the trial was to occur if the lower bound of the 95% confidence interval (CI) for VE(7-24) was >0%. Adverse events (AEs) were collected post each vaccination. Serious AEs and AEs of special interest (AESIs) were collected throughout the trial.
A total of 2637 women (1323 placebo, 1314 vaccine), with a median age of 23 years, were enrolled at 23 sites. Baseline characteristics were similar across arms with ∼3% detectable intracellular tenofovir disoproxil fumarate levels. HIV-1 incidence between Month 7 and 24 in the PP cohort was 4.3 per 100 person-years in the placebo arm versus 3.6 in the vaccine arm (Figure). VE(7-24) was 25.2% (95% CI: -10.5% to 49.4%). The vaccine was well tolerated with mild local reactogenicity (mild/moderate pain/tenderness: 23% placebo, 50% vaccine). Mild/moderate systemic symptoms were reported by 56% and 66% in the placebo and vaccine arms, respectively. No vaccine-related serious AEs or AESIs were reported.